Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27139 | 0.97 | RECQL (0.32) | RECQLMEN1CYP2D6KMT2APOLB | |
| SCHEMBL30968097 | 0.92 | POLB (0.35) | RECQLMEN1CYP2D6KMT2APOLB | |
| SCHEMBL31231682 | 0.89 | ALDH1A1 (0.36) | RECQLMEN1CYP2D6KMT2AGAA | |
| Ammonia Solution, Strong SCHEMBL18049530 | 0.89 | POLB (0.34) | RECQLMEN1CYP2D6KMT2APOLB | |
| SCHEMBL3710945 | 0.88 | CHRM2 (0.31) | CHRM2CHRM1CHRM3 | |
| SCHEMBL20958537 | 0.83 | CHRM2 (0.44) | MEN1CYP2D6KMT2APOLBGAA | |
| SCHEMBL1165401 | 0.83 | CHRM2 (0.44) | MEN1CYP2D6KMT2APOLBGAA | |
| SCHEMBL20958534 | 0.83 | CHRM2 (0.44) | MEN1CYP2D6KMT2APOLBGAA | |
| SCHEMBL4686451 | 0.83 | SLC6A1 (0.34) | ALDH1A1LMNAGLAHPGD | |
| SCHEMBL1165403 | 0.83 | CHRM2 (0.44) | MEN1CYP2D6KMT2APOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3638658-B1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-10-08 | — | — | EP | claimed |
| WO-2026101897-A1 | 6-(6-{[(1R,2R,3S,5S)-2-FLUORO-8-AZABICYCLO[3.2.1 ]OCTAN-3-YL] (METHYL)AMINO }PYRIDAZIN-3-YL)-2-METHYL-L,3-BENZOXAZOL-5-OL TO TREAT HUNTINGTON'S DISEASE | SKYHAWK THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-116003441-B | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-06-10 | — | — | CN | disclosed |
| WO-2024259171-A9 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| CN-115925705-B | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-12172994-B2 | Pyrimidine compound as JAK kinase inhibitor | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2024259171-A2 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024182747-A2 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240158389-A1 | PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-3958969-B1 | ESTER AND CARBONATE PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-01-10 | — | — | EP | disclosed |
| US-9975890-B2 | Bicyclic AZA compounds as muscarinic M1 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-05-22 | — | — | US | disclosed |
| US-20170247369-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-08-31 | — | — | US | disclosed |
| US-9669013-B2 | Bicyclic aza compounds as muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| EP-3083625-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | Almac Discovery Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| US-20160128996-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| US-9266857-B2 | Bicyclic AZA compounds as muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-20150232443-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| WO-2015092431-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
| WO-2011003007-A1 | AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010114958-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158389-A1 | PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR | JAK1, JAK2, JAK3 | RECQL 2260/4885MEN1 4213/4885CYP2D6 1764/4885 |
| US-12172994-B2 | Pyrimidine compound as JAK kinase inhibitor | JAK1, JAK2, JAK3 | RECQL 2260/4885MEN1 4213/4885CYP2D6 1764/4885 |
| US-20150232443-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM5 | RECQL 1405/4885MEN1 990/4885CYP2D6 491/4885 |
| US-20170247369-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | RECQL 1376/4885MEN1 921/4885CYP2D6 476/4885 |
| US-20160128996-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM5 | RECQL 1405/4885MEN1 990/4885CYP2D6 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.